Multi-Institutional Implementation of Clinical Decision Support for APOL1, NAT2, and YEATS4 Genotyping in Antihypertensive Management
暂无分享,去创建一个
Allison B McCoy | Carol R Horowitz | Lori A Orlando | Khoa A Nguyen | Girish N Nadkarni | Paul R Dexter | Michael T Eadon | Victoria M Pratt | Stuart A Scott | Joseph L Kannry | Thomas M Schneider | Rhonda M Cooper-DeHoff | Kerri L Cavanaugh | Meghan J Arwood | Emma M Tillman | A. McCoy | P. Dexter | G. Nadkarni | R. Cooper-DeHoff | C. Horowitz | J. Kannry | V. Pratt | M. Eadon | K. Cavanaugh | L. Orlando | Meghan J. Arwood | E. Tillman | K. Nguyen | S. Scott | Thomas M. Schneider
[1] S. Waring,et al. Primary Care Clinicians Attitudes and Knowledge of Pharmacogenetics in a Large, Multi-state, Healthcare System. , 2018, Innovations in pharmacy.
[2] G. Ginsburg,et al. Primary care providers' use of pharmacist support for delivery of pharmacogenetic testing. , 2017, Pharmacogenomics.
[3] J. Peterson,et al. Clinician Perspectives on Using Pharmacogenomics in Clinical Practice. , 2015, Personalized medicine.
[4] Marc B Rosenman,et al. Lessons Learned When Introducing Pharmacogenomic Panel Testing into Clinical Practice. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[5] E. Boerwinkle,et al. Association of Chromosome 12 locus with antihypertensive response to hydrochlorothiazide may involve differential YEATS4 expression , 2012, The Pharmacogenomics Journal.
[6] David W. Bates,et al. Synthesis of Research Paper: Ten Commandments for Effective Clinical Decision Support: Making the Practice of Evidence-based Medicine a Reality , 2003, J. Am. Medical Informatics Assoc..
[7] Barry I. Freedman,et al. APOL1 risk variants, race, and progression of chronic kidney disease. , 2013, The New England journal of medicine.
[8] L. Appel,et al. Strict blood pressure control associates with decreased mortality risk by APOL1 genotype. , 2017, Kidney international.
[9] B. Freedman,et al. The Impact of APOL1 on Chronic Kidney Disease and Hypertension. , 2019, Advances in chronic kidney disease.
[10] Michael T. Eadon,et al. Genotype-Guided Hydralazine Therapy , 2020, American Journal of Nephrology.
[11] P. Suffys,et al. Different phenotypes of the NAT2 gene influences hydralazine antihypertensive response in patients with resistant hypertension. , 2014, Pharmacogenomics.
[12] Rennie Negron,et al. Determining the effects and challenges of incorporating genetic testing into primary care management of hypertensive patients with African ancestry. , 2016, Contemporary clinical trials.
[13] Giulio Genovese,et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. , 2011, Journal of the American Society of Nephrology : JASN.
[14] P. Deloukas,et al. Integrating Genome-Wide Genetic Variations and Monocyte Expression Data Reveals Trans-Regulated Gene Modules in Humans , 2011, PLoS genetics.
[15] Ebony B Madden,et al. Opportunities to implement a sustainable genomic medicine program: lessons learned from the IGNITE Network , 2018, Genetics in Medicine.
[16] E. Boerwinkle,et al. Hypertensive APOL1 risk allele carriers demonstrate greater blood pressure reduction with angiotensin receptor blockade compared to low risk carriers , 2019, PloS one.
[17] Ebony B Madden,et al. Establishing the Value of Genomics in Medicine – The IGNITE Pragmatic Trials Network , 2021, Genetics in Medicine.
[18] M. Fornage,et al. APOL1 variants associate with increased risk of CKD among African Americans. , 2013, Journal of the American Society of Nephrology : JASN.
[19] Andre Kushniruk,et al. A Framework for Usable and Effective Clinical Decision Support: Experience from the iCPR Randomized Clinical Trial , 2015, EGEMS.
[20] J. Marc Overhage,et al. Details of a Successful Clinical Decision Support System , 2007, AMIA.
[21] Janet E Olson,et al. Integrating Pharmacogenomics into Clinical Practice: Promise vs Reality. , 2016, The American journal of medicine.
[22] R. Altman,et al. Implementing Personalized Medicine: Development of a Cost‐Effective Customized Pharmacogenetics Genotyping Array , 2012, Clinical pharmacology and therapeutics.
[23] R. Freimuth,et al. Implementing Genomic Clinical Decision Support for Drug‐Based Precision Medicine , 2017, CPT: pharmacometrics & systems pharmacology.
[24] Randolph A. Miller,et al. Focus on health information technology, electronic health records and their financial impact: A framework for evaluating the appropriateness of clinical decision support alerts and responses , 2012, J. Am. Medical Informatics Assoc..
[25] Brooke L. Fridley,et al. Genomic Association Analysis Suggests Chromosome 12 Locus Influencing Antihypertensive Response to Thiazide Diuretic , 2008, Hypertension.
[26] C. Winkler,et al. Genetic Testing for APOL1 Genetic Variants in Clinical Practice: Finally Starting to Arrive. , 2019, Clinical journal of the American Society of Nephrology : CJASN.